{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:06:39Z","timestamp":1792069599518,"version":"4.4.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG054080, R01AG064614, U01AG052410, P50AG008702,"],"award-info":[{"award-number":["RF1AG054080, R01AG064614, U01AG052410, P50AG008702,"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AG052410, RF1AG054074"],"award-info":[{"award-number":["U01AG052410, RF1AG054074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015569","name":"Canadian Consortium on Neurodegeneration in Aging","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015569","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Early-onset Alzheimer\u2019s disease (EOAD), defined as Alzheimer\u2019s disease (AD) occurring before age 65, is significantly less well studied than the late-onset form (LOAD) despite EOAD often presenting with a more aggressive disease progression. The aim of this review is to summarize the current understanding of the etiology of EOAD, their translation into clinical practice, and to suggest steps to be taken to move our understanding forward.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>\n                      EOAD cases make up 5\u201310% of AD cases but only 10\u201315% of these cases show known mutations in the\n                      <jats:italic>APP<\/jats:italic>\n                      ,\n                      <jats:italic>PSEN1<\/jats:italic>\n                      , and\n                      <jats:italic>PSEN2<\/jats:italic>\n                      , which are linked to EOAD. New data suggests that these unexplained cases following a non-Mendelian pattern of inheritance is potentially caused by a mix of common and newly discovered rare variants. However, only a fraction of this genetic variation has been identified to date leaving the molecular mechanisms underlying this type of AD and their association with clinical, biomarker, and neuropathological changes unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>While great advancements have been made in characterizing EOAD, much work is needed to disentangle the molecular mechanisms underlying this type of AD and to identify putative targets for more precise disease screening, diagnosis, prevention, and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11910-020-01090-y","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T01:03:05Z","timestamp":1611018185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Early-Onset Alzheimer\u2019s Disease: What Is Missing in Research?"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-934X","authenticated-orcid":false,"given":"Temitope","family":"Ayodele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-0329","authenticated-orcid":false,"given":"Ekaterina","family":"Rogaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6291-3911","authenticated-orcid":false,"given":"Jiji T.","family":"Kurup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7061-6332","authenticated-orcid":false,"given":"Gary","family":"Beecham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"1090_CR1","unstructured":"World Health Organization 2019 10 facts on dementia 2019 [."},{"issue":"3","key":"1090_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","volume":"15","author":"Alzheimer\u2019s Association","year":"2019","unstructured":"Alzheimer\u2019s Association. 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;15(3):321\u201387.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1090_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/archneurol.2011.221","volume":"69","author":"TS Wingo","year":"2012","unstructured":"Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012;69(1):59\u201364.","journal-title":"Arch Neurol"},{"issue":"215","key":"1090_CR4","first-page":"e1","volume":"49","author":"IS Barber","year":"2017","unstructured":"Barber IS, Braae A, Clement N, Patel T, Guetta-Baranes T, Brookes K, et al. Mutation analysis of sporadic early-onset Alzheimer\u2019s disease using the NeuroX array. Neurobiol Aging. 2017;49(215):e1\u20138.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1090_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/alzrt63","volume":"3","author":"K Szigeti","year":"2011","unstructured":"Szigeti K, Doody RS. Should EOAD patients be included in clinical trials? Alzheimers Res Ther. 2011;3(1):4.","journal-title":"Alzheimers Res Ther"},{"key":"1090_CR6","volume-title":"Early-onset dementia: a national challenge, a future crisis","author":"A Alzheimer's","year":"2006","unstructured":"Alzheimer's A. Early-onset dementia: a national challenge, a future crisis. Wash\u00adingto\u00adn, DC: Alzheimer's Association; 2006."},{"issue":"3","key":"1090_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","volume":"7","author":"C Reitz","year":"2011","unstructured":"Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137\u201352.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1090_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/ene.12325","volume":"21","author":"MA Lambert","year":"2014","unstructured":"Lambert MA, Bickel H, Prince M, Fratiglioni L, Von Strauss E, Frydecka D, et al. Estimating the burden of early onset dementia; systematic review of disease prevalence. Eur J Neurol. 2014;21(4):563\u20139.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1090_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/gps.2456","volume":"26","author":"E Renvoize","year":"2011","unstructured":"Renvoize E, Hanson M, Dale M. Prevalence and causes of young onset dementia in an English health district. Int J Geriatr Psychiatry. 2011;26(1):106\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"1090_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25(1):59\u201370.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1090_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S1474-4422(10)70306-9","volume":"10","author":"WM van der Flier","year":"2011","unstructured":"van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer\u2019s disease: the case of the missing APOE \u025b4 allele. Lancet Neurol. 2011;10(3):280\u20138.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1090_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer\u2019s disease: a review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther. 2011;3(1):1.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1090_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2217\/bmm.09.92","volume":"4","author":"NS Ryan","year":"2010","unstructured":"Ryan NS, Rossor MN. Correlating familial Alzheimer\u2019s disease gene mutations with clinical phenotype. Biomark Med. 2010;4(1):99\u2013112.","journal-title":"Biomark Med"},{"issue":"1","key":"1090_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0891988706297086","volume":"20","author":"GA Marshall","year":"2007","unstructured":"Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer\u2019s disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol. 2007;20(1):29\u201333.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"3","key":"1090_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253\u201360.","journal-title":"Neurology."},{"issue":"1","key":"1090_CR16","volume":"12","author":"AJ Aschenbrenner","year":"2020","unstructured":"Aschenbrenner AJ, Petros J, McDade E, Wang G, Balota DA, Benzinger TL, et al. Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimers Dement (Amst). 2020;12(1):e12038.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"1090_CR17","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"1090_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"MK Chen","year":"2018","unstructured":"Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75(10):1215\u201324.","journal-title":"JAMA Neurol."},{"issue":"8925","key":"1090_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","volume":"344","author":"MJ West","year":"1994","unstructured":"West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer\u2019s disease. Lancet. 1994;344(8925):769\u201372.","journal-title":"Lancet."},{"issue":"7","key":"1090_CR20","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169(7):1276\u201390e17.","journal-title":"Cell"},{"issue":"7638","key":"1090_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481\u20137.","journal-title":"Nature."},{"issue":"7","key":"1090_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrn.2017.48","volume":"18","author":"K Kisler","year":"2017","unstructured":"Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419\u201334.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1090_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270\u20136.","journal-title":"Nat Med"},{"key":"1090_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.arr.2016.01.002","volume":"30","author":"L Pini","year":"2016","unstructured":"Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain atrophy in Alzheimer\u2019s disease and aging. Ageing Res Rev. 2016;30:25\u201348.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"1090_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0006-8993(00)03082-1","volume":"888","author":"Y Arai","year":"2001","unstructured":"Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer\u2019s disease: morphology and its relationship to tau aggregation. Brain Res. 2001;888(2):287\u201396.","journal-title":"Brain Res"},{"issue":"5","key":"1090_CR26","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00415-015-7698-3","volume":"262","author":"A Palas\u00ed","year":"2015","unstructured":"Palas\u00ed A, Guti\u00e9rrez-Iglesias B, Alegret M, Pujadas F, Olabarrieta M, Li\u00e9bana D, et al. Differentiated clinical presentation of early and late-onset Alzheimer\u2019s disease: is 65 years of age providing a reliable threshold? J Neurol. 2015;262(5):1238\u201346.","journal-title":"J Neurol"},{"issue":"8","key":"1090_CR27","doi-asserted-by":"publisher","first-page":"a021766","DOI":"10.1101\/cshperspect.a021766","volume":"7","author":"LR Squire","year":"2015","unstructured":"Squire LR, Genzel L, Wixted JT, Morris RG. Memory consolidation. Cold Spring Harb Perspect Biol. 2015;7(8):a021766.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9","key":"1090_CR28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785\u201396.","journal-title":"Lancet Neurol"},{"issue":"22","key":"1090_CR29","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","volume":"360","author":"GM Savva","year":"2009","unstructured":"Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302\u20139.","journal-title":"N Engl J Med"},{"issue":"19","key":"1090_CR30","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1212\/WNL.0b013e318236f0cf","volume":"77","author":"LE Middleton","year":"2011","unstructured":"Middleton LE, Grinberg LT, Miller B, Kawas C, Yaffe K. Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology. 2011;77(19):1737\u201344.","journal-title":"Neurology."},{"issue":"9","key":"1090_CR31","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/archneur.65.9.1211","volume":"65","author":"V Haroutunian","year":"2008","unstructured":"Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 2008;65(9):1211\u20137.","journal-title":"Arch Neurol"},{"issue":"4","key":"1090_CR32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/neup.12205","volume":"35","author":"NJ Cairns","year":"2015","unstructured":"Cairns NJ, Perrin RJ, Franklin EE, Carter D, Vincent B, Xie M, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology. 2015;35(4):390\u2013400.","journal-title":"Neuropathology."},{"issue":"3","key":"1090_CR33","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1086\/302553","volume":"65","author":"D Campion","year":"1999","unstructured":"Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65(3):664\u201370.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"1090_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","volume":"63","author":"M Gatz","year":"2006","unstructured":"Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168\u201374.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1090_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1533317514545825","volume":"30","author":"AI Jarmolowicz","year":"2015","unstructured":"Jarmolowicz AI, Chen HY, Panegyres PK. The patterns of inheritance in early-onset dementia: Alzheimer\u2019s disease and frontotemporal dementia. Am J Alzheimers Dis Other Dement. 2015;30(3):299\u2013306.","journal-title":"Am J Alzheimers Dis Other Dement"},{"issue":"6311","key":"1090_CR36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u20136.","journal-title":"Nature."},{"issue":"6534","key":"1090_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature. 1995;375(6534):754\u201360.","journal-title":"Nature."},{"key":"1090_CR38","doi-asserted-by":"crossref","unstructured":"Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science. 1995;269(5226):973\u20137.","DOI":"10.1126\/science.7638622"},{"issue":"5","key":"1090_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/mp.2008.96","volume":"14","author":"KA Bates","year":"2009","unstructured":"Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, et al. Clearance mechanisms of Alzheimer\u2019s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry. 2009;14(5):469\u201386.","journal-title":"Mol Psychiatry"},{"issue":"26","key":"1090_CR40","doi-asserted-by":"publisher","first-page":"7931","DOI":"10.1021\/bi060799c","volume":"45","author":"MS Wolfe","year":"2006","unstructured":"Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry. 2006;45(26):7931\u20139.","journal-title":"Biochemistry."},{"issue":"2","key":"1090_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2007.10.012","volume":"131","author":"DJ Selkoe","year":"2007","unstructured":"Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131(2):215\u201321.","journal-title":"Cell."},{"issue":"5441","key":"1090_CR42","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.286.5441.916","volume":"286","author":"C Haass","year":"1999","unstructured":"Haass C, De Strooper B. The presenilins in Alzheimer's disease--proteolysis holds the key. Science. 1999;286(5441):916\u20139.","journal-title":"Science."},{"issue":"4","key":"1090_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrn785","volume":"3","author":"SS Sisodia","year":"2002","unstructured":"Sisodia SS, St George-Hyslop PH. Gamma-Secretase, Notch, Abeta and Alzheimer\u2019s disease: where do the presenilins fit in? Nat Rev Neurosci. 2002;3(4):281\u201390.","journal-title":"Nat Rev Neurosci"},{"issue":"7409","key":"1090_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488(7409):96\u20139.","journal-title":"Nature."},{"issue":"5920","key":"1090_CR45","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.1168979","volume":"323","author":"G Di Fede","year":"2009","unstructured":"Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science. 2009;323(5920):1473\u20137.","journal-title":"Science."},{"issue":"1","key":"1090_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ng1718","volume":"38","author":"A Rovelet-Lecrux","year":"2006","unstructured":"Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerri\u00e8re A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24\u20136.","journal-title":"Nat Genet"},{"issue":"23","key":"1090_CR47","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1212\/01.wnl.0000339400.64213.56","volume":"71","author":"I Guyant-Marechal","year":"2008","unstructured":"Guyant-Marechal I, Berger E, Laquerri\u00e8re A, Rovelet-Lecrux A, Viennet G, Frebourg T, et al. Intrafamilial diversity of phenotype associated with app duplication. Neurology. 2008;71(23):1925\u20136.","journal-title":"Neurology."},{"issue":"4","key":"1090_CR48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm0498-452","volume":"4","author":"R Crook","year":"1998","unstructured":"Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, et al. A variant of Alzheimer\u2019s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4(4):452\u20135.","journal-title":"Nat Med"},{"issue":"4","key":"1090_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1212\/WNL.57.4.621","volume":"57","author":"EA Rogaeva","year":"2001","unstructured":"Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology. 2001;57(4):621\u20135.","journal-title":"Neurology."},{"issue":"8","key":"1090_CR50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/hmg\/8.8.1529","volume":"8","author":"C De Jonghe","year":"1999","unstructured":"De Jonghe C, Cruts M, Rogaeva EA, Tysoe C, Singleton A, Vanderstichele H, et al. Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer\u2019s disease by increased Abeta42 secretion. Hum Mol Genet. 1999;8(8):1529\u201340.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"1090_CR51","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/archneur.62.12.1821","volume":"62","author":"BJ Snider","year":"2005","unstructured":"Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, et al. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol. 2005;62(12):1821\u201330.","journal-title":"Arch Neurol"},{"key":"1090_CR52","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.dadm.2018.07.007","volume":"10","author":"R Cheng","year":"2018","unstructured":"Cheng R, Tang M, Martinez I, Ayodele T, Baez P, Reyes-Dumeyer D, et al. Linkage analysis of multiplex Caribbean Hispanic families loaded for unexplained early-onset cases identifies novel Alzheimer\u2019s disease loci. Alzheimers Dement (Amst). 2018;10:554\u201362.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"1090_CR53","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/mp.2012.15","volume":"17","author":"C Pottier","year":"2012","unstructured":"Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry. 2012;17(9):875\u20139.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1090_CR54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ana.24305","volume":"77","author":"BN Vardarajan","year":"2015","unstructured":"Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M, et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol. 2015;77(2):215\u201327.","journal-title":"Ann Neurol"},{"issue":"6","key":"1090_CR55","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/mp.2015.121","volume":"21","author":"G Nicolas","year":"2016","unstructured":"Nicolas G, Charbonnier C, Wallon D, Quenez O, Bellenguez C, Grenier-Boley B, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Mol Psychiatry. 2016;21(6):831\u20136.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1090_CR56","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00401-016-1566-9","volume":"132","author":"J Verheijen","year":"2016","unstructured":"Verheijen J, Van den Bossche T, van der Zee J, Engelborghs S, Sanchez-Valle R, Llad\u00f3 A, et al. A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer\u2019s disease. Acta Neuropathol. 2016;132(2):213\u201324.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1090_CR57","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00401-016-1615-4","volume":"132","author":"OM Andersen","year":"2016","unstructured":"Andersen OM, Rudolph IM, Willnow TE. Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease. Acta Neuropathol. 2016;132(5):653\u201365.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"1090_CR58","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452\u20138.","journal-title":"Nat Genet"},{"issue":"2","key":"1090_CR59","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/ng1943","volume":"39","author":"E Rogaeva","year":"2007","unstructured":"Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168\u201377.","journal-title":"Nat Genet"},{"issue":"1","key":"1090_CR60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/archneurol.2010.346","volume":"68","author":"C Reitz","year":"2011","unstructured":"Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhiro S, Zou F, et al. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 2011;68(1):99\u2013106.","journal-title":"Arch Neurol"},{"issue":"2","key":"1090_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00401-019-01991-4","volume":"138","author":"D Campion","year":"2019","unstructured":"Campion D, Charbonnier C, Nicolas G. SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. Acta Neuropathol. 2019;138(2):173\u201386.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1090_CR62","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000116","volume":"2","author":"ML Cuccaro","year":"2016","unstructured":"Cuccaro ML, Carney RM, Zhang Y, Bohm C, Kunkle BW, Vardarajan BN, et al. SORL1 mutations in early- and late-onset Alzheimer disease. Neurol Genet. 2016;2(6):e116.","journal-title":"Neurol Genet"},{"issue":"1","key":"1090_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/ADR-200177","volume":"4","author":"K Barthelson","year":"2020","unstructured":"Barthelson K, Newman M, Lardelli M. Sorting out the role of the sortilin-related receptor 1 in Alzheimer\u2019s disease. J Alzheimers Dis Rep. 2020;4(1):123\u201340.","journal-title":"J Alzheimers Dis Rep"},{"issue":"3","key":"1090_CR64","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330.","journal-title":"Nat Genet"},{"issue":"5123","key":"1090_CR65","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133.","journal-title":"Science."},{"issue":"7616","key":"1090_CR66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285\u201391.","journal-title":"Nature."},{"issue":"8","key":"1090_CR67","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ejhg.2017.87","volume":"25","author":"H Holstege","year":"2017","unstructured":"Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer\u2019s disease: a clinical interpretation strategy. Eur J Hum Genet. 2017;25(8):973\u201381.","journal-title":"Eur J Hum Genet"},{"issue":"220","key":"1090_CR68","first-page":"e1","volume":"59","author":"C Bellenguez","year":"2017","unstructured":"Bellenguez C, Charbonnier C, Grenier-Boley B, Quenez O, Le Guennec K, Nicolas G, et al. Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging. 2017;59(220):e1\u20139.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1090_CR69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"M Gratuze","year":"2018","unstructured":"Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13(1):66.","journal-title":"Mol Neurodegener"},{"issue":"13","key":"1090_CR70","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1038\/npp.2014.164","volume":"39","author":"T Jiang","year":"2014","unstructured":"Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer\u2019s disease. Neuropsychopharmacology. 2014;39(13):2949\u201362.","journal-title":"Neuropsychopharmacology."},{"key":"1090_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1750-1326-9-20","volume":"9","author":"JD Ulrich","year":"2014","unstructured":"Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20.","journal-title":"Mol Neurodegener"},{"issue":"243","key":"1090_CR72","doi-asserted-by":"publisher","first-page":"243ra86","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra86.","journal-title":"Sci Transl Med"},{"issue":"12","key":"1090_CR73","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jalz.2014.12.009","volume":"11","author":"CM Lill","year":"2015","unstructured":"Lill CM, Rengmark A, Pihlstr\u00f8m L, Fogh I, Shatunov A, Sleiman PM, et al. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement. 2015;11(12):1407\u201316.","journal-title":"Alzheimers Dement"},{"key":"1090_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"F Kametani","year":"2018","unstructured":"Kametani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease. Front Neurosci. 2018;12:25.","journal-title":"Front Neurosci"},{"issue":"10","key":"1090_CR75","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1093\/brain\/awy238","volume":"141","author":"M Zhang","year":"2018","unstructured":"Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U, et al. A C6orf10\/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain. 2018;141(10):2895\u2013907.","journal-title":"Brain."},{"key":"1090_CR76","doi-asserted-by":"crossref","unstructured":"Bergsma T and Rogaeva E. DNA methylation clocks and their predictive capacity for ageing phenotypes and healthspan. Neuroscience Insights, 2020 (Submitted).","DOI":"10.1177\/2633105520942221"},{"issue":"10","key":"1090_CR77","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","volume":"14","author":"S Horvath","year":"2013","unstructured":"Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.","journal-title":"Genome Biol"},{"issue":"12","key":"1090_CR78","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.18632\/aging.100859","volume":"7","author":"S Horvath","year":"2015","unstructured":"Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of Parkinson\u2019s disease patients. Aging. 2015;7(12):1130\u201342.","journal-title":"Aging."},{"issue":"7","key":"1090_CR79","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.18632\/aging.101005","volume":"8","author":"S Horvath","year":"2016","unstructured":"Horvath S, Langfelder P, Kwak S, Aaronson J, Rosinski J, Vogt TF, et al. Huntington\u2019s disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. Aging (Albany NY). 2016;8(7):1485\u2013512.","journal-title":"Aging (Albany NY)"},{"key":"1090_CR80","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00401-017-1713-y","volume":"134","author":"M Zhang","year":"2017","unstructured":"Zhang M, Tartaglia MC, Moreno D, Sato C, McKeever P, Weichert A, et al. DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients. Acta Neuropathol. 2017;134:271\u20139.","journal-title":"Acta Neuropathol"},{"key":"1090_CR81","doi-asserted-by":"crossref","unstructured":"Zhang M, McKeever PM, Xi Z, Moreno D, Sato C, Bergsma T, et al. DNA methylation age acceleration is associated with ALS age of onset and survival. Acta Neuropathol. 2020;139(5):943\u20136","DOI":"10.1007\/s00401-020-02131-z"},{"issue":"12","key":"1090_CR82","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.18632\/aging.100864","volume":"7","author":"ME Levine","year":"2015","unstructured":"Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive functioning. Aging. 2015;7(12):1198\u2013211.","journal-title":"Aging."},{"key":"1090_CR83","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neurobiolaging.2017.02.009","volume":"55","author":"S Degerman","year":"2017","unstructured":"Degerman S, Josefsson M, Nordin Adolfsson A, Wennstedt S, Landfors M, Haider Z, et al. Maintained memory in aging is associated with young epigenetic age. Neurobiol Aging. 2017;55:167\u201371.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"1090_CR84","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1093\/brain\/awz289","volume":"142","author":"M Zhang","year":"2019","unstructured":"Zhang M, Dilliott AA, Khallaf R, Robinson JF, Hegele RA, Comishen M, et al. Genetic and epigenetic study of an Alzheimer's disease family with monozygotic triplets. Brain. 2019;142(11):3375\u201381.","journal-title":"Brain."},{"issue":"6","key":"1090_CR85","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643\u201363.","journal-title":"J Intern Med"},{"issue":"5","key":"1090_CR86","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology."},{"issue":"4","key":"1090_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/alzrt268","volume":"6","author":"M Allen","year":"2014","unstructured":"Allen M, Kachadoorian M, Quicksall Z, Zou F, Chai HS, Younkin C, et al. Association of MAPT haplotypes with Alzheimer\u2019s disease risk and MAPT brain gene expression levels. Alzheimers Res Ther. 2014;6(4):39.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1090_CR88","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s13760-017-0816-5","volume":"117","author":"E Niemantsverdriet","year":"2017","unstructured":"Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S. Alzheimer\u2019s disease CSF biomarkers: clinical indications and rational use. Acta Neurol Belg. 2017;117(3):591\u2013602.","journal-title":"Acta Neurol Belg"},{"issue":"1","key":"1090_CR89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of a beta 42(43) and a beta 40 in senile plaques with end-specific a beta monoclonals: evidence that an initially deposited species is a beta 42(43). Neuron. 1994;13(1):45\u201353.","journal-title":"Neuron."},{"issue":"14","key":"1090_CR90","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91(14):e1295\u2013e306.","journal-title":"Neurology."},{"issue":"7","key":"1090_CR91","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1090_CR92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/alzrt162","volume":"5","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements - a desired but elusive Alzheimer\u2019s disease biomarker. Alzheimers Res Ther. 2013;5(2):8.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1090_CR93","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3233\/JAD-170531","volume":"62","author":"L Shi","year":"2018","unstructured":"Shi L, Baird AL, Westwood S, Hye A, Dobson R, Thambisetty M, et al. A decade of blood biomarkers for Alzheimer\u2019s disease research: an evolving field, improving study designs, and the challenge of replication. J Alzheimers Dis. 2018;62(3):1181\u201398.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1090_CR94","doi-asserted-by":"publisher","first-page":"177","DOI":"10.31887\/DCNS.2019.21.2\/hhampel","volume":"21","author":"H Hampel","year":"2019","unstructured":"Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Arenas J, Benda N, et al. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer\u2019s disease. Dialogues Clin Neurosci. 2019;21(2):177\u201391.","journal-title":"Dialogues Clin Neurosci"},{"issue":"8","key":"1090_CR95","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"key":"1090_CR96","doi-asserted-by":"crossref","unstructured":"Nabers A, Perna L, Lange J, Mons U, Schartner J, Guldenhaupt J, et al. Amyloid blood biomarker detects Alzheimer\u2019s disease. EMBO Mol Med. 2018;10(5).","DOI":"10.15252\/emmm.201708763"},{"key":"1090_CR97","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019.","DOI":"10.1001\/jamaneurol.2019.1632"},{"issue":"9","key":"1090_CR98","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y, et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(9):353\u201364.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"1090_CR99","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gissl\u00e9n","year":"2016","unstructured":"Gissl\u00e9n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135\u201340.","journal-title":"EBioMedicine."},{"issue":"5","key":"1090_CR100","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer\u2019s disease neuroimaging I. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1090_CR101","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383.","journal-title":"Nat Med"},{"key":"1090_CR102","doi-asserted-by":"crossref","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med. 338;2016(8):338ra66.","DOI":"10.1126\/scitranslmed.aaf2362"},{"issue":"9","key":"1090_CR103","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.0000000000003050","volume":"87","author":"JP Chhatwal","year":"2016","unstructured":"Chhatwal JP, Schultz AP, Marshall GA, Boot B, Gomez-Isla T, Dumurgier J, et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology. 2016;87(9):920\u20136.","journal-title":"Neurology."},{"issue":"Pt 8","key":"1090_CR104","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/brain\/aww139","volume":"139","author":"BA Gordon","year":"2016","unstructured":"Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139(Pt 8):2249\u201360.","journal-title":"Brain."},{"issue":"4","key":"1090_CR105","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"47","key":"1090_CR106","doi-asserted-by":"publisher","first-page":"E4502","DOI":"10.1073\/pnas.1317918110","volume":"110","author":"TL Benzinger","year":"2013","unstructured":"Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 1","key":"1090_CR107","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/brain\/awq310","volume":"134","author":"WD Knight","year":"2011","unstructured":"Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain. 2011;134(Pt 1):293\u2013300.","journal-title":"Brain"},{"key":"1090_CR108","doi-asserted-by":"crossref","unstructured":"Rowley PA, Samsonov AA, Betthauser TJ, Pirasteh A, Johnson SC, Eisenmenger LB. Amyloid and Tau PET imaging of Alzheimer disease and other neurodegenerative conditions. Seminars in Ultrasound, CT and MRI. 2020.","DOI":"10.1053\/j.sult.2020.08.011"},{"issue":"4","key":"1090_CR109","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awz019","volume":"142","author":"BA Gordon","year":"2019","unstructured":"Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, et al. Tau PET in autosomal dominant Alzheimer\u2019s disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142(4):1063\u201376.","journal-title":"Brain."},{"issue":"8","key":"1090_CR110","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.neurobiolaging.2013.02.013","volume":"34","author":"C Moller","year":"2013","unstructured":"Moller C, Vrenken H, Jiskoot L, Versteeg A, Barkhof F, Scheltens P, et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer\u2019s disease. Neurobiol Aging. 2013;34(8):2014\u201322.","journal-title":"Neurobiol Aging"},{"issue":"Pt 2","key":"1090_CR111","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/brain\/awp326","volume":"133","author":"GD Rabinovici","year":"2010","unstructured":"Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain. 2010;133(Pt 2):512\u201328.","journal-title":"Brain."},{"key":"1090_CR112","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neurobiolaging.2017.01.024","volume":"53","author":"H Cho","year":"2017","unstructured":"Cho H, Choi JY, Lee SH, Lee JH, Choi YC, Ryu YH, et al. Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer\u2019s disease. Neurobiol Aging. 2017;53:103\u201311.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"1090_CR113","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/brain\/awx171","volume":"140","author":"M Scholl","year":"2017","unstructured":"Scholl M, Ossenkoppele R, Strandberg O, Palmqvist S, Fs SB, Jogi J, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain. 2017;140(9):2286\u201394.","journal-title":"Brain"},{"issue":"8","key":"1090_CR114","doi-asserted-by":"publisher","first-page":"e42325","DOI":"10.1371\/journal.pone.0042325","volume":"7","author":"D Holland","year":"2012","unstructured":"Holland D, Desikan RS, Dale AM, LK ME. Alzheimer\u2019s Disease Neuroimaging I. Rates of decline in Alzheimer disease decrease with age. PLoS One. 2012;7(8):e42325.","journal-title":"PLoS One"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-020-01090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-020-01090-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-020-01090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T05:34:45Z","timestamp":1674884085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-020-01090-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s11910-020-01090-y","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"18 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Temitope Ayodele, Ekaterina Rogaeva, Jiji T. Kurup, Gary Beecham, and Christiane Reitz declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"4"}}